Choose setting Age - children, all phases Age - children, phase I Age - children, phase II Age - children, phase III Age - elderly, all phases Expanded acess study Fatigue first-line - all first-line - all, excluding chemo or transplant frontline - antibody, excluding chemo or transplant first-line - transplant First-line - vaccine Grade I (most indolent) Grade II Grade III (least indolent) Grade - indolent, recurrent Grade - indolent, untreated Grade - aggressive, recurrent Phase - all Phase - all, excluding chemo Phase I studies Phase I, excluding chemo Phase II Phase II, excluding chemo Phase III Phase IV studies Phase III, excluding chemo Stage - any specified Stage I Stage I - with radiotherapy Stage II Stage II - with radiotherapy Stage III Stage III - with radiotherapy Stage IV Stage IV - with radiotherapy Refractory - all Refractory - all - allogeneic SCT Refractory - all - autologous SCT Refractory - all - immune-therapy Refractory - all - mini SCT Refractory - aggressive NHL Refractory - CLL Refractory - CLL - allogeneic SCT Refractory - Hodgkin's Refractory - Hodgkin's - allogeneic SCT Refractory - Hodgkin's - autologous SCT Refractory - Hodgkin's - mini SCT Refractory - indolent NHL Refractory - NHL - allogeneic SCT Refractory - NHL - autologous SCT Refractory - NHL - mini SCT Refractory - T-cell Refractory - T-cell - allogeneic SCT Refractory - T-cell - autologous SCT Refractory - T-cell - mini SCT